ACA
IMVT icon

Atlas Capital Advisors’s Immunovant IMVT Stock Holding History

Atlas Capital Advisors’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,000
Closed -$8.69K – 948
2021
Q3 		$8.69K Hold
1,000
– – ﹤0.01% 745
2021
Q2 		$10.6K Buy
+1,000
New +$14K ﹤0.01% 734
2021
Q1 		– Sell
-1,900
Closed -$87.8K – 807
2020
Q4 		$87.8K Buy
+1,900
New +$87.8K 0.02% 409

Other funds holding IMVT

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Atlas Capital Advisors's IMVT Position: Q4 2021 in Review

Atlas Capital Advisors sold out of Immunovant (IMVT) in Q4 2021, closing a stake of 1,000 shares — an estimated $8.69K sold.

Atlas Capital Advisors first reported a position in IMVT in Q4 2020 and held it in 3 quarters. The position peaked at $87.8K in Q4 2020. 118 funds tracked by Wall St. Rank hold IMVT as of Q4 2021.

  • Atlas Capital Advisors reported no remaining Immunovant position as of Q4 2021 after selling out during the quarter.
  • Atlas Capital Advisors sold 1,000 Immunovant shares in Q4 2021, an estimated $8.69K.
  • Atlas Capital Advisors first reported a position in Immunovant in Q4 2020 and held it in 3 quarters.
  • Atlas Capital Advisors's Immunovant position peaked at $87.8K in Q4 2020.
  • 118 funds tracked by Wall St. Rank held Immunovant as of Q4 2021.

Based on Atlas Capital Advisors's 13F filing for Q4 2021, filed 1 Feb 2022.